Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

174
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
174
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

307
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
307
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

212
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
212
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

460
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
460
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

205
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
205

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical look at disease classification/diagnosis criteria in rheumatology.

Current opinion in immunology·2026
Same author

Behçet's Syndrome.

Current rheumatology reports·2026
Same author

Assessing Rheumatoid Arthritis Disease Activity Measures in Ethnic Minority Patients in the United States: Real-World Data From the Ethnic Minority Rheumatoid Arthritis Consortium Registry.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2025
Same author

Can we cure Behçet syndrome?

Current opinion in immunology·2025
Same author

Correspondence on 'Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis' by Nagle et al.

Annals of the rheumatic diseases·2025
Same author

A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.

Clinical and experimental rheumatology·2025

Related Experiment Video

Updated: Jan 15, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

526

Treatment of systemic vasculitis.

Yusuf Yazici1

  • 1Clinical Associate Professor of Medicine, NYU Grossman School of Medicine, New York, New York, USA.

Current Opinion in Rheumatology
|October 10, 2025
PubMed
Summary

New treatments show promise for systemic vasculitis, including ANCA-associated vasculitis (AAV). However, issues with new classification criteria need addressing for widespread adoption in clinical trials.

Keywords:
ANCA-associated vasculitisTakayasu arteritisclassification criteriagiant cell arteritispolymyalgia rheumaticatreatment guidelines

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.3K

Related Experiment Videos

Last Updated: Jan 15, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

526
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.3K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic vasculitis encompasses several rare autoimmune diseases.
  • Effective management of vasculitis requires up-to-date treatment strategies.

Purpose of the Study:

  • To review recent impactful data on treating systemic vasculitic conditions.
  • Focus on ANCA-associated vasculitis (AAV), giant cell arteritis, polymyalgia rheumatica, and Takayasu arteritis.

Main Methods:

  • Review of recent clinical trials and real-world registry data.
  • Analysis of new classification criteria for vasculitic conditions.

Main Results:

  • Several agents (rituximab, cyclophosphamide, upadacitinib, baricitinib, mepolizumab, benralizumab, tocilizumab) demonstrated treatment benefits.
  • New classification criteria for AAV, giant cell arteritis, and Takayasu arteritis have methodological issues hindering adoption.

Conclusions:

  • Emerging data offer potential to transform systemic vasculitis management.
  • Addressing current limitations in classification criteria is crucial for patient care and research.